Pneumocystis jirovecii pneumonia

FDA-Approved Treatments

The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition. Learn more orphan products.

• Atovaquone (Brand name: Mepron®) - Manufactured by Glaxo Wellcome Inc.
  FDA-approved indication: For the acute oral treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in patients who are intolerant to trimethoprim-sulfamethoxazole. Prevention of PCP in patients who are intolerant to trimethoprim-sulfamethoxazole.
  National Library of Medicine Drug Information Portal
• Pentamidine isethionate (Brand name: Nebupent®) - Manufactured by APP Pharmaceuticals
  FDA-approved indication: Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.
  National Library of Medicine Drug Information Portal
  Medline Plus Health Information
• Trimetrexate glucuronate (Brand name: Neutrexin®) - Manufactured by Medimmune Oncology, Inc.
  FDA-approved indication: Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients who are intolerant of, or are refractory to, trimethoprim sulfamethoxazole.
  National Library of Medicine Drug Information Portal
  Medline Plus Health Information
• Pentamidine isethionate (Brand name: Pentam 300®) - Manufactured by APP Pharmaceuticals
  FDA-approved indication: Treatment of Pneumocystis carinii pneumonia.
  National Library of Medicine Drug Information Portal
  Medline Plus Health Information